• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
ViiV Healthcare - Product Pipeline Review - Q1 2011 Product Image

ViiV Healthcare - Product Pipeline Review - Q1 2011

  • ID: 1590048
  • March 2011
  • 37 pages
  • Global Markets Direct

ViiV Healthcare – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “ViiV Healthcare - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ViiV Healthcare - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ViiV Healthcare human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across READ MORE >



List of Tables
List of Figures
ViiV Healthcare Snapshot
ViiV Healthcare Overview
Key Information
Key Facts
ViiV Healthcare – Research and Development Overview
Key Therapeutic Areas
ViiV Healthcare – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ViiV Healthcare – Pipeline Products Glance
ViiV Healthcare – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
ViiV Healthcare Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ViiV Healthcare – Drug Profiles
1349572
Product Description
Mechanism of Action
R&D Progress
572-Trii
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
PF-232798
Product Description
Mechanism of Action
R&D Progress
S/GSK1265744
Product Description
Mechanism of Action
R&D Progress
UK-453061
Product Description
Mechanism of Action
R&D Progress
PF-3716539
Product Description
Mechanism of Action
R&D Progress
ViiV Healthcare – Pipeline Analysis
ViiV Healthcare – Pipeline Products by Therapeutic Class
ViiV Healthcare - Pipeline Products By Target
ViiV Healthcare – Pipeline Products by Route of Administration
ViiV Healthcare – Pipeline Products by Molecule Type
ViiV Healthcare – Recent Pipeline Updates
ViiV Healthcare - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
2248761
ViiV Healthcare – Locations And Subsidiaries
Head Office
Recent Developments
Nov 23, 2010: Idenix Receives $20 Million Milestone Payment From ViiV Healthcare For Initiation Of Phase IIb Trial Of '761
Oct 21, 2010: Shionogi-ViiV Initiates Phase III Clinical Program For Investigational Once-Daily HIV Integrase Inhibitor
Jul 22, 2010: Shionogi-ViiV Presents Positive Data From Two Phase IIb Studies Of S/GSK1349572 At International AIDS Conference
Jul 21, 2010: Shionogi-ViiV Healthcare Initiates Phase III Development Program For S/GSK1349572 In Treatment Of HIV
Dec 22, 2009: GSK warned that Lexiva may be associated with cardiac problems
Dec 22, 2009: GSK warned that Lexiva may be associated with cardiac problems
Dec 22, 2009: GSK warned that Lexiva may be associated with cardiac problems
Nov 20, 2009: FDA Approves Expanded Use of Selzentry for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time
Oct 08, 2009: FDA Advisory Committee Recommends Approval of Pfizer’s Selzentry for Use in Patients Starting HIV Therapy for the First Time
Jul 21, 2009: 96-Week MERIT ES Analysis Shows Efficacy Of Pfizer’s HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naïve HIV Patients; Results Consistent With 48-Week Analysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
ViiV Healthcare – Pipeline by Therapy Area and Indication, 2011
ViiV Healthcare – Pipeline by Stage of Development, 2011
ViiV Healthcare – Monotherapy Products in Pipeline, 2011
ViiV Healthcare – Phase III, 2011
ViiV Healthcare - Phase II, 2011
ViiV Healthcare - Phase I, 2011
ViiV Healthcare - Pipeline By Therapeutic Class, 2011
ViiV Healthcare - Pipeline By Target, 2011
ViiV Healthcare – Pipeline By Route of Administration, 2011
ViiV Healthcare – Pipeline By Molecule Type, 2011
ViiV Healthcare – Recent Pipeline Updates, 2011
ViiV Healthcare - Discontinued Pipeline Products, 2010

List of Figures
ViiV Healthcare – Pipeline by Therapy Area and Indication, 2011
ViiV Healthcare – Pipeline by Stage of Development, 2011
ViiV Healthcare – Monotherapy Products in Pipeline, 2011
ViiV Healthcare – Pipeline By Therapeutic Class, 2011
ViiV Healthcare - Pipeline By Target, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos